David Olson

David Olson

Company: Delix Therapeutics

Job title: Chief Innovation Officer

Seminars:

Panel Discussion: Reflection on Hallucinations & Impact on Efficacy to Guide Development 3:45 pm

Is the hallucinatory aspect of psychedelics merely undesirable or mandatory? What are the future implications for expansion of 3rd Generation Psychedelics? What further research is required to address this fundamental query?Read more

day: Day Two

Non-Hallucinogenic Psychoplastogens 3:15 pm

Appreciating the role of neural plasticity in the sustained therapeutic effects of psychedelics and related compounds Exploring medicinal chemistry of known psychedelic compounds to avoid hallucinogenic effects and cardiotoxicity Understanding the mechanism of psychedelic-induced neural plasticityRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.